On January 1, 2026, FUJIFILM Irvine Scientific officially adopted the legal name FUJIFILM Biosciences Inc., reflecting its evolution from a pioneer in cell culture media to a broader life-science solutions provider. The rebranding underscores a 55-year heritage in cell culture innovation, with the company now offering a comprehensive portfolio spanning cell culture media, feeds, specialty chemicals, single-use technologies and human-induced pluripotent stem cell services. FUJIFILM Biosciences operates a global network of manufacturing facilities and leverages ongoing capital investments to accelerate development of biotherapeutic processes and advance life-changing treatments, supporting customers from discovery through commercialization.

Shares of Fujifilm Holdings (OTCMKTS:FUJIY) gapped up at the open on Friday, driven by a strong analyst upgrade and continued earnings momentum. Trading volume reached 4,171 shares as Zacks Research raised its rating from Hold to Strong Buy, contributing to a consensus Strong Buy view. The company’s market capitalization stands at $26.5 billion, with a P/E ratio of 8.1, a PEG of 1.79 and a beta of 0.76. Liquidity metrics include a current ratio of 1.38 and a quick ratio of 0.87, while debt-to-equity is a conservative 0.16. In its most recent quarter, Fujifilm reported earnings per share that exceeded analysts’ consensus by $0.58 and revenues of $5.33 billion, generating a net margin of 8.3% and a return on equity of 7.9%. Equities research analysts project full-year EPS of 0.66, reinforcing positive sentiment around the company’s diversified imaging, industrial materials and healthcare businesses.